| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 108.39 | 83.8% |
| Total Income | 108.39 | 83.8% |
| Expenditure | 90.55 | 47.8% |
| PBT | 18.51 | 575.8% |
| Net Profit | 17.97 | 550.4% |
| OPM | 16.45% | 20.38pp |
| NPM | 16.58% | 23.34pp |
| EPS | 0.39 | 200.0% |
BillionToOne Reports Q1 2026 Revenue Up 84% and Raises 2026 Guidance
07 May 2026 · 7 May, 1:49 am
Summary
BillionToOne reported strong financial results for the first quarter of 2026, with total revenue increasing by 84% to $108.4 million. The growth was driven by significant increases in both prenatal and oncology clinical testing revenue. Gross profit margin also improved to 73%. The company raised its full year 2026 revenue guidance to $450 million to $465 million, reflecting expected growth of 48% to 52% over 2025.
Key Highlights
- 1
BillionToOne's total revenue reached $108.4 million in the first quarter of 2026, marking an 84% increase compared to $59.0 million in the first quarter of 2025.
- 2
Prenatal clinical testing revenue increased by 72% to $96.5 million in the first quarter of 2026.
- 3
Oncology clinical testing revenue more than quadrupled to $10.7 million in the first quarter of 2026 from $2.2 million in the first quarter of 2025.
- 4
Gross profit margin improved to 73% in the first quarter of 2026, a 9 percentage-point increase from 64% in the first quarter of 2025.
- 5
The company delivered 188,000 tests in the first quarter of 2026, a 44% increase from 131,000 tests in the first quarter of 2025.
- 6
Income from operations was $17.8 million in the first quarter of 2026, compared to a $2.3 million operating loss in the first quarter of 2025.
- 7
BillionToOne raised its full year 2026 revenue guidance to a range of $450 million to $465 million, representing 48% to 52% growth over 2025.
Management Comments
Dr. Oguzhan Atay
"Our first quarter performance underscores the continued momentum we are building through our differentiated technology platform, category-defining products, and disciplined execution," said Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne. "In Q1 2026 we launched additional prenatal and oncology offerings and significantly expanded our payor contracts, reaching $300 million contracted lives in the U.S. We remain focused on addressing some of healthcare’s most complex challenges. As we move through 2026, we believe we are only beginning to realize the full potential of our platform.”
Informational and educational content only. Not investment advice.